A Type 1 diabetes command-center workspace with glucose supplies, a laptop, and a CGM.
For T1D families

What changed in Type 1 diabetes today.

Research, trials, devices, and safety notices — labeled by evidence strength so you can tell solid science from hype.

1158
library articles
200
signals tracked
8
cure programs
7
evidence labels
Last updated: Thursday, September 3, 2026Updates every 6 hours
Today's priorities

Start here — highest-signal items first.

Pulled from official registries and public research sources, then labeled by evidence strength before publication.

Your focus topics

Saved on this device only. Matching items rise on Today. No health profile required.

Live updates

What is moving right now.

32 items from 4 live sources. Updated Sep 3, 2026, 11:42 AM CDT.

openFDA device recallsok
10 items
ClinicalTrials.govok
10 items
PubMedok
12 items
Crossrefok
0 items
SafetyActT0

Medtronic MiniMed, Inc.: MiniMed 640G Insulin Pump, Model: MMT-1711, MMT-1712;

openFDA device recalls/Aug 17, 2026/FDA recall database

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Medtronic MiniMed, Inc.: MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782;

openFDA device recalls/Aug 17, 2026/FDA recall database

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, Model: MMT-1885CLW, MMT-1886CLW

openFDA device recalls/Aug 17, 2026/FDA recall database

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
TrialsActT0

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

ClinicalTrials.gov/Aug 11, 2026/Official recruiting registry

RECRUITING, PHASE2. Interventions: Dulaglutide, Placebo. Locations: Orlando, Florida, United States. The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Why it matters: Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.
Open original source
TrialsActT0

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

ClinicalTrials.gov/Aug 9, 2026/Official recruiting registry

RECRUITING, PHASE2. Interventions: Tirzepatide 2.5mg weekly, Placebo injection (normal saline). Locations: Sydney, New South Wales, Australia. This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during th...

Why it matters: Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.
Open original source
SafetyActT0

Medtronic MiniMed, Inc.: MiniMed Go App, Model: MMT-8600 (iOS), MMT-8601 (Android)

openFDA device recalls/Jul 22, 2026/FDA recall database

For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This could result in missed rapid-acting insulin doses without the user s knowledge, and may lead to delayed therapy and an increased risk of hyperglycemia. Action: On 6/16/2026 In-App Push Notifications were sent to customers entitled, Important Field Safety Corrective Action required on your MiniMed Go ap...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
TrialsActT0

Changing Outpatient Diabetes Care With Remote-Patient-Monitoring: A Real World Evidence Study With Pre-Post Comparison

ClinicalTrials.gov/Jul 16, 2026/Official recruiting registry

RECRUITING. Interventions: Remote-Patient-Monitoring (RPM). Locations: Herlev, Denmark. The goal of this observational pre-post study is to evaluate a remote-patient-monitoring-system (RPM-system) integrated within an electronic health record (EHR) system in a real world cohort of approximately 12.000 people with diabetes in an outpatient care setting. The main question it aims to answer is: Whether glycemic outcomes following integration of the RPM syste...

Why it matters: Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.
Open original source
SafetyActT0

Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, REF: MMT-1885, MMT-1886, MMT-1895, MMT-1896

openFDA device recalls/Jul 7, 2026/FDA recall database

A software anomaly can occur when the pump is paired with the Instinct sensor. Under certain circumstances, the pump unexpectedly stops delivering insulin and displays two error messages back-to-back: Pump Error 53 followed immediately by Pump Error 23. Insulin delivery will stop which may lead to delayed therapy and an increased risk of hyperglycemia or diabetic ketoacidosis... Action: On 5/27/2026, field safety notices were emailed to customers who were asked to do the following: 1) Update insulin pump software...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Insulet Corporation: Omnipod 5 Pods. Includes the below Model/REF Numbers: 1. POD-OMNI-I1-6720. 2. POD-OMNI-I1-6220. 3. OMNI-I1-6729 (10-Pack), OMNI-I1-6720 (Single Pod). 4. OMNI-I1-6220. 5. OMNI-I1-6...

openFDA device recalls/Jun 29, 2026/FDA recall database

External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an "Urgent: Medical Device Correction" on the same day. Consig...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Insulet Corporation: Omnipod DASH Pod. Includes the below Model/REF Numbers: 1. POD-BLE-I1-525 (5-Pack), POD-BLE-I1-520 (Single Pod). 2. POD-BLE-I1-529 (10-Pack), POD-BLE-I1-520 (Single Pod). 3. BLE-I...

openFDA device recalls/Jun 29, 2026/FDA recall database

External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an "Urgent: Medical Device Correction" on the same day. Consig...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Insulet Corporation: Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420...

openFDA device recalls/Jun 29, 2026/FDA recall database

External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an "Urgent: Medical Device Correction" on the same day. Consig...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
SafetyActT0

Dexcom, Inc.: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Software Version: N/A Produ...

openFDA device recalls/Jun 23, 2026/FDA recall database

Certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process. The sensors were later sold to pharmacies and distributors by Pharmsource, LLC. Lot 1725204004 were designated for destruction because the G7 sensors were not properly sterilized and have an increased risk of skin infection if used. Lot 1725... Action: On 05/26-27/2026, the firm issued a Press Release and sent an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" informing custome...

Why it matters: Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.
Open original source
Cure & AdvancementsTrackNews report — unverified, pending corroboration

Living in the In-Between: How People Are Coping While Type 1 Diabetes Research Advances

beyondtype1.org

Promising research is happening on multiple fronts, yet people managing Type 1 diabetes today still face daily management challenges. Understanding how to hold hope and present reality together matters.

Cure & AdvancementsTrackVideo report, corroborated with 4 indexed studies

July 2026 Research Spotlight: Five Advances Reshaping Type 1 Diabetes Care

YouTube / This Month in Type 1 Diabetes Research

From transplant breakthroughs to digital tools and caregiver insights, recent research is expanding treatment options and revealing what helps young people manage their condition better.

Cure & AdvancementsTrackNews report — unverified, pending corroboration

One Family's Type 1 Diabetes Diagnosis: The Signs That Changed Everything

Northeast and Western Wisconsin Chapter

Oliver Zilinskas was 10 years old when subtle symptoms—fatigue, thirst, weight loss—came together to reveal a Type 1 diabetes diagnosis. His family's story shows why recognizing these warning signs matters.

Cure & AdvancementsTrackNews report, corroborated with 5 indexed studies

Stem Cell Therapy Shows Promise in Restoring Insulin Production for Type 1 Diabetes

wam.ae

Researchers are making significant progress developing insulin-producing cells from stem cells that can regulate blood sugar in laboratory and animal studies. Early human trials are underway to test whether this approach can reduce or eliminate the need for insulin injections.

Brooke's Story

Chapter 5 — Age 17

Almost seventeen: what I'd tell a newly diagnosed kid

Closing in on seventeen, here's the short version of everything the younger me needed to hear.

Closing in on seventeen, here's the short version of everything the younger me needed to hear.

Brooke's chapters are personal lived experience shared to make people feel less alone. They are not medical advice and do not describe a treatment plan. Talk to your own care team about your numbers, devices, and decisions.

Safety priority

Recalls and device alerts outrank everything.

If FDA, MedWatch, or a manufacturer issues a relevant CGM, pump, app, insulin, or glucagon alert, it should bypass the normal feed and hit the family alert lane first.

Medtronic MiniMed, Inc.

Medtronic MiniMed, Inc.: MiniMed 640G Insulin Pump, Model: MMT-1711, MMT-1712;

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Open alert

Medtronic MiniMed, Inc.

Medtronic MiniMed, Inc.: MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782;

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Open alert

Medtronic MiniMed, Inc.

Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, Model: MMT-1885CLW, MMT-1886CLW

Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...

Open alert

Medtronic MiniMed, Inc.

Medtronic MiniMed, Inc.: MiniMed Go App, Model: MMT-8600 (iOS), MMT-8601 (Android)

For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This could result in missed rapid-acting insulin doses without the user s knowledge, and may lead to delayed therapy and an increased risk of hyperglycemia. Action: On 6/16/2026 In-App Push Notifications were sent to customers entitled, Important Field Safety Corrective Action required on your MiniMed Go ap...

Open alert
Early access

Build the daily T1D brief around your family's watchlist.

The first launch list will receive source-backed research, trial, device, safety, and community alerts. No diagnosis questionnaire, no PHI sale, and no miracle-cure marketing.

Consent-first alerts before any future trial-matching workflow.
Free digest first; premium intelligence only after trust is earned.
Alert topics

Choose the alerts you want first. No health profile is required.